|
Display additional annotations [+]
|
| |
Figure S8. CST Is Required for Proper Cell Growth of Cardiomyocytes Dorsal to
the Cardiac Ventral Midline
(A) Representative transverse sections of Stage 29 control MO (top) and CstMO
(bottom) injected embryos stained with MHC antibody to mark differentiated
cardiomyocytes, phospho-histone H3 (pH3) antibody to mark cardiac cells in the Mphase
of the cell cycle, and DAPI. Bracket highlights undifferentiated cardiac ventral
midline cells. (B) CST-depleted differentiated cardiomyocytes have an increased mitotic
index at Stage 29. Quantification of the mitotic index was determined by calculating the
percentage of pH3-positive differentiated cardiomyocytes. Bars represent the average
of at least three embryos per condition +/- SEM. *, p<0.01; Scale bars: 200 μm. |
|
|
| |
Figure S5. Morpholino Design and Phenotype
(A) Position of the Cst splice junction morpholinos relative to the pre-mRNA transcripts
targeting the donor the exon 8 (ex8D MO) and the acceptor of exon 9 (ex9A MO),
referred collectively as CstMO. (B) Position of the Cst-5′ UTR morpholinos (red) relative
to the Cstα and Cstβ cDNA transcripts. (C-D) Whole mount antibody staining with anti-
MHC of Stage 32 control MO (C) and Cstα/β MO (D) embryos (ventral view) indicating
an identical cardia bifida phenotype is obtained with both the CstMO (splice MO) as the
Cstα/β MO (5′ UTR MO). Scale bar: C = 100 μm. |
